<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03559569</url>
  </required_header>
  <id_info>
    <org_study_id>7031</org_study_id>
    <nct_id>NCT03559569</nct_id>
  </id_info>
  <brief_title>Impact of Endothelial and Leukocyte Senescence in Circulatory Shock States</brief_title>
  <acronym>Seneshock</acronym>
  <official_title>Impact of Endothelial and Leukocyte Senescence in Circulatory Shock States</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Circulatory shocks (CS) are life-threatening, acute organ dysfunction. Advances in critical
      care medicine have decreased early hospital mortality, increasing the number of surviving
      patients. Regrettably, these survivors are at increased risk of new infections but also of
      cardiovascular disease.

      The investigators hypothesize that CS with multi-organ dysfunction is associated with
      premature senescence of endothelial cells and immune cells and promotes endothelial
      thrombogenicity and immunosenescence leading to cardiovascular disease and secondary
      infections.

      The aim of this work is therefore to evaluate the contribution of endothelial and leucocytes
      senescence to the occurrence of secondary events (infectious and cardiovascular) in patients
      with a CS. It will provide a better understanding of the pathogenesis of cardiovascular and
      immune diseases following a CS, likely to guide new management strategies to prevent their
      occurrence.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 7, 2019</start_date>
  <completion_date type="Anticipated">March 2025</completion_date>
  <primary_completion_date type="Anticipated">February 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The main criterion will be the acquisition of a senescent phenotype concerning leukocytes and endothelial cells.</measure>
    <time_frame>1 year</time_frame>
    <description>Biological samples will be done to evaluate the endothelial and leukocyte senescence.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of cardiovascular events and secondary infection in hospitalized patients in intensive care unit for circulatory shock states</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">520</enrollment>
  <condition>Shock</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Infection</condition>
  <arm_group>
    <arm_group_label>Patients with circulatory shock</arm_group_label>
    <description>500 patients with circulatory shock hospitalize in ICU will be prospectively included to assess the effect of this pathology on the senescence phenotype</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <description>20 healthy volunteers will be included to assess the effect of no pathology on the senescence phenotype.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Biological samples will be done to evaluate the endothelial and leukocyte senescence.</intervention_name>
    <description>Noninvasive, reproducible, and sensitive methods to measure cardiac function, endothelial function, and arterial stiffness will be assess.</description>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_label>Patients with circulatory shock</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Only whole blood will be collected
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All patients admitted in the intensive care unit of the &quot;Nouvel Hôpital Civil de
        Strasbourg&quot; for a circulatory shock will be included.

        Healthy volunteer will be included in our Clinical Investigation Center of the &quot;Hôpitaux
        Universitaires de Strasbourg&quot;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Circulatory shock

          -  patient with health care insurance

        Exclusion criteria:

          -  Patients' refusal to participate in clinical research

          -  Pregnant woman

          -  Breastfeeding woman

          -  A patient with a protective order
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ferhat MEZIANI</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpitaux Universitaires de Strasbourg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Barbara JUNG</last_name>
    <phone>03 88 11 68 55</phone>
    <phone_ext>+33</phone_ext>
    <email>barbara.jung@chru-strasbourg.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Madoé JULIANS</last_name>
    <phone>03 88 11 61 86</phone>
    <phone_ext>+33</phone_ext>
    <email>madoe.julians@chru-strasbourg.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Strasbourg - Service de Réanimation médicale du NHC</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ferhat MEZIANI</last_name>
      <phone>03 69 55 10 24</phone>
      <phone_ext>+33</phone_ext>
      <email>ferhat.meziani@chru-strasbourg.fr</email>
    </contact>
    <contact_backup>
      <last_name>Hamid MERDJI</last_name>
      <phone>03 69 55 11 23</phone>
      <phone_ext>+33</phone_ext>
      <email>hamid.merdji@chru-strasbourg.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Ferhat MEZIANI</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hamid MERDJI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laure STIEL</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xavier DELABRANCHE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christine KUMMERLEN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hassène RAHMANI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexandra MONNIER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yannick RABOUEL</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julie HELMS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Raphaël CLERE-JEHL</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dominique STEPHAN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sébastien GAERTNER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Catherine MUTTER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>May 17, 2018</study_first_submitted>
  <study_first_submitted_qc>June 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2018</study_first_posted>
  <last_update_submitted>March 11, 2019</last_update_submitted>
  <last_update_submitted_qc>March 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Shock</keyword>
  <keyword>Cardiovascular Diseases</keyword>
  <keyword>Infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

